Ellomay Capital grants 1,000 stock options to director
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Ellomay Capital Ltd. director Daniel Vaknin received an annual grant of 1,000 stock options on August 1, 2026 under the Issuer's 1998 Share Option Plan for Non-Employee Directors. The options have a $19.60 exercise price, become exercisable August 1, 2027, are subject to his continued board service on that date, and expire August 1, 2036, leaving him with 1,000 options.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) F1, F2 | 1,000 | $0.00 | $0.00 |
Footnotes (2)
- F1. On August 1, 2026, the Reporting Person received an annual grant of options under the terms and conditions set forth in the Issuer's 1998 Share Option Plan for Non-Employee Directors.
- F2. Subject to the Reporting Person serving as a member of the Issuer's Board of Directors on such date.
Key Figures
Key Terms
Stock Option (right to buy) financial
exercise price financial
expiration date financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What transaction did Ellomay Capital (ELLO) director Daniel Vaknin report?
What is the exercise price of Daniel Vaknin’s Ellomay Capital (ELLO) stock options?
When do Daniel Vaknin’s newly granted Ellomay Capital (ELLO) options become exercisable?
When do the Ellomay Capital (ELLO) director stock options granted to Daniel Vaknin expire?
How many Ellomay Capital (ELLO) stock options does Daniel Vaknin hold after this grant?
What condition affects Daniel Vaknin’s ability to exercise his Ellomay Capital (ELLO) options?
AI-generated analysis. How Rhea-AI works. Not financial advice.